Endo International plc s in-depth stock price analysis indicates that the stock price has dropped -29.64% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -42.65% . Looking at the past 52 week period, the stock price is down -75.92% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Endo International plc has a negative value of -41.49 compared to overall market performance. Endo International plc (NASDAQ:ENDP) has tumbled 5.11% during the past week and has dropped 8.57% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 5.88%. Endo International plc (NASDAQ:ENDP) has underperformed the index by 10.2% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Endo International plc (NASDAQ:ENDP) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.12 points or 0.99% at $12.06 with 5,196,360 shares getting traded. Post opening the session at $12.12, the shares hit an intraday low of $12.05 and an intraday high of $12.26 and the price was in this range throughout the day. The company has a market cap of $2,688 million and the number of outstanding shares has been calculated to be 222,876,800 shares. The 52-week high of Endo International plc (NASDAQ:ENDP) is $54.79 and the 52-week low is $11.37.
Endo International plc – Ordinary Shares Last issued its quarterly earnings results on Nov 8, 2016. The company reported $1.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.20. Analyst had a consensus of $0.81. The company had revenue of $884.30 million for the quarter, compared to analysts expectations of $862.89 million. The companys revenue was up 18.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.02 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Endo International plc – Ordinary Shares was Reiterated by Mizuho on Jan 31, 2017 to Buy, Lowers Price Target to $ 15 from a previous price target of $25 .Endo International plc – Ordinary Shares was Downgraded by JP Morgan to Neutral on Jan 20, 2017. Endo International plc – Ordinary Shares was Downgraded by Citigroup to Neutral on Jan 5, 2017. Endo International plc – Ordinary Shares was Resumed by Oppenheimer to Perform on Dec 7, 2016.
Company has reported several Insider transactions to the SEC, on Nov 16, 2016, Roger H Kimmel (director) sold 14,000 shares at 17.79 per share price.On May 18, 2016, Douglas S Ingram (director) sold 4,513 shares at 26.59 per share price.On May 12, 2016, Arthur J Higgins (director) purchased 5,000 shares at 13.80 per share price.
Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, womens health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.